- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
Patent holdings for IPC class A61P 33/02
Total number of patents in this class: 967
10-year publication summary
|
45
|
51
|
62
|
69
|
68
|
83
|
70
|
53
|
49
|
26
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 10279 |
20 |
| CEVA Sante Animale | 718 |
15 |
| Anacor Pharmaceuticals, Inc. | 53 |
11 |
| Universidade Federal de Minas Gerais - Ufmg | 193 |
11 |
| Consejo Superior de Investigaciones Cientificas (csic) | 1442 |
10 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 3001 |
10 |
| Centre National de La Recherche Scientifique | 11010 |
9 |
| Fundacao Oswaldo Cruz | 109 |
9 |
| Nihon Nohyaku Co., Ltd. | 325 |
9 |
| Bayer Animal Health GmbH | 174 |
8 |
| Universidad de Granada | 307 |
8 |
| University of Dundee | 218 |
8 |
| Zivo BioScience, Inc. | 56 |
8 |
| Kimberly-clark Worldwide, Inc. | 5300 |
7 |
| Glaxosmithkline Intellectual Property Development Limited | 777 |
7 |
| The Board of Trustees of the Leland Stanford Junior University | 6652 |
7 |
| President and Fellows of Harvard College | 6085 |
7 |
| CJ Cheiljedang Corporation | 3630 |
7 |
| Griffith University | 160 |
7 |
| Institut de Recherche pour le Developpement (ird) | 150 |
7 |
| Other owners | 782 |